How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

799 results for

Galantamine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

761. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. (PubMed)

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. The objective of the study was to study the effects of acetylcholinesterase inhibitors on cognition in patients with schizophrenia. We conducted a 12-week, double-blind, placebo-controlled trial of galantamine as adjunctive treatment to conventional antipsychotic drugs on 24 patients with schizophrenia. The 24 patients had (...) been stabilized on conventional antipsychotic drugs (chlorpromazine equivalent dose of 1390 mg/day) for a minimum of 3 months before their enrollment into the study. The patients were evaluated at baseline, and after 6 and 12 weeks using the Korean version of Mini Mental State Examination, Brief Psychiatric Rating Scale, and a standard neuropsychological battery. Compared with placebo, galantamine produced a small and nonsignificant change in the cognitive measures, but the score for recognition

2007 International clinical psychopharmacology

762. Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers. (PubMed)

Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers. A randomized, two-way, crossover study was conducted in 18 healthy male Chinese volunteers to compare pharmacokinetics profiles of galantamine hydrobromide dispersible tablet with that of conventional tablet. A single oral dose of 10 mg galantamine was administrated to each volunteer. Plasma concentrations of galantamine were determined by a validated high-performance

2007 Drug development and industrial pharmacy

763. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. (PubMed)

Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. To understand how commonly diminution of verbal repetition was a goal of treatment in patients with Alzheimer disease (AD), how commonly that goal was achieved, whether goal attainment might be attributable to galantamine treatment, and whether change in verbal repetition is a marker of the overall treatment response.This is a secondary analysis of the Video-Imaging Synthesis of Treating Alzheimer's (...) Disease study, a 4-month, double-blind, randomized, placebo-controlled trial of galantamine in 130 community-dwelling patients with mild to moderate AD. The primary outcome was Goal Attainment Scaling, in which individualized problems identified by patients/caregivers and treating physicians were assessed bimonthly.Reduction of verbal repetition was set as a treatment goal in 44% (n = 57) of randomized patients. More patients/caregivers (32%) set repetition goals than did physicians (18%). After 4

2007 Neurology

764. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. (PubMed)

Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. The high morbidity and mortality caused by smoking highlights the importance of investigating new strategies for smoking cessation or reduction. Galantamine is an acetylcholinesterase inhibitor that increases the effect of acetylcholine (ACh). The nicotinic ACh receptor is activated via positive allosteric modulation (APL).We investigated whether galantamine reduces smoking by performing a 24-week (...) galantamine (n = 56) or placebo (n = 58) for 12 weeks. Follow-up examinations were terminated after an additional 12 weeks without treatment. Smoking behavior did not differ between both groups at baseline. After treatment, the intention-to-treat analysis revealed significant differences with a 20% lower cumulative number of smoked cigarettes and a 15% lower number of smoking days in the galantamine group compared to placebo. The average number of smoked cigarettes per smoking day as well as the cotinine

2006 International journal of clinical pharmacology and therapeutics

765. Galantamine treatment of vascular dementia: a randomized trial. (PubMed)

Galantamine treatment of vascular dementia: a randomized trial. To evaluate efficacy and safety of galantamine for patients with vascular dementia (VaD).In this multinational, randomized, double-blind, placebo-controlled, parallel-group clinical trial, 788 patients with probable VaD who also satisfied strict centrally read MRI criteria were randomized to receive galantamine or placebo. Efficacy was evaluated using measures of cognition, daily function, and behavior. The primary efficacy (...) measures were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog/11) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) total score. Secondary outcomes included the Clinician's Interview Based on Impression of Change-Plus Caregiver Input (CIBIC-plus), Neuropsychiatric Inventory, and EXIT-25 for assessment of executive functioning. Safety and tolerability were also monitored.Patients treated with galantamine had a greater improvement in ADAS

2007 Neurology

766. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. (PubMed)

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. The management of dementia in Alzheimer's disease has dramatically changed since the development of anti-dementia drugs. However, there is limited information available regarding the bio-medical aspects of the differing drugs; particularly relating to adults with intellectual disability. Indeed (...) the information available for the intellectual disabled population is limited to adults with Down syndrome. This review highlights the important pharmacological and clinical aspects of donepezil, rivastigmine, galantamine and memantine and supports the view that such drugs play an important part in the management of dementia in adults with intellectual disability. Future clinical and research issues are discussed.Copyright 2004 John Wiley & Sons, Ltd.

2004 International Journal of Geriatric Psychiatry

767. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. (PubMed)

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Cholinesterase inhibitors with additional nicotinic activity, such as galantamine, may be useful in PD patients with dementia (PDD) since stimulation of nicotinic receptors may prevent the down-regulation that is likely to accompany cholinesterase inhibition and facilitate dopamine release in the striatum.Sixteen PDD patients (six female) with onset of cognitive impairment after at least one year (...) with parkinsonism participated in this open-label trial of galantamine. Cognitive, psychiatric, and motor symptoms were assessed before and after 8 weeks of treatment with galantamine using unstructured clinical assessment as well as rating scales including the Mini-Mental State Examination (MMSE), clock drawing test, verbal fluency and selected items from the Neuropsychiatric Inventory (NPI).Age (mean, SD) was 75.6 (5.2) years, duration of PD 13.4 (5.9), duration of dementia 2.1 (1.7) years, Hoehn and Yahr

2003 International Journal of Geriatric Psychiatry

768. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. (PubMed)

Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. Lacking long-term placebo-controlled trials of cholinesterase inhibitors (ChEIs) in Alzheimer's disease, how decline is modeled is crucial to interpreting the effects of long-term, open-label use. We aimed to: 1) understand changes in cognition and function in people taking galantamine; (2) identify treatment subgroups.This is an open-label long-term extension (up to 48 (...) months) of two placebo-controlled clinical trials from Europe and Canada. At baseline, 240 patients with mild-moderate Alzheimer's disease at baseline had received galantamine continuously for 36 months. The trajectory of scores on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Disability Assessment for Dementia (DAD) was modeled over 48 months. Goodness of fit was compared using normalized residuals and by calculating correlation coefficients between observed

2007 International Journal of Geriatric Psychiatry

769. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. (PubMed)

Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Regional brain correlates of treatment with cholinesterase inhibitors in those with Alzheimer disease are unknown.To map brain metabolism associated with the treatment response to galantamine with fludeoxyglucose F 18 positron emission tomography in patients with Alzheimer disease.This is a hypothesis-driven, prospective, open-label study of 19 patients (...) with mild to moderate Alzheimer disease examined before and after treatment with the cholinesterase inhibitor galantamine. Clinical examinations included the cognitive portion of the Alzheimer Disease Assessment Scale, the Mini-Mental State Examination, and the Neuropsychiatric Inventory. Imaging was performed using fludeoxyglucose F 18 positron emission tomography. The positron emission tomographic data, registered to a probabilistic anatomical atlas, were subjected to a voxel-based analysis of 3

Full Text available with Trip Pro

2005 Archives of Neurology

770. Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. (PubMed)

Preclinical investigation of the functional effects of memantine and memantine combined with galantamine or donepezil. Combinations of drugs approved to treat Alzheimer's disease (AD) were tested in older rabbits with delay eyeblink classical conditioning, a form of associative learning severely impaired in AD. In Experiment 1 (n=49 rabbits), low doses (0.1, 0.5, 1.0, and 0.0 (vehicle) mg/kg) of memantine (Namenda) were tested. These three doses neither improved nor impaired acquisition (...) at a statistically significant level. The 0.5 mg/kg dose had the greatest effect numerically and did not cause sensitization or habituation in explicitly unpaired controls. In Experiment 2 (n=56), doses of galantamine (Razadyne; 3.0 mg/kg) and donepezil (Aricept; 0.75 mg/kg) that had comparable magnitudes of cholinesterase inhibition were tested alone and in combination with 0.5 mg/kg memantine. Older rabbits treated with galantamine and with galantamine+memantine learned significantly better than vehicle

Full Text available with Trip Pro

2007 Neuropsychopharmacology

771. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. (PubMed)

The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Galantamine, a drug for Alzheimer's disease, is a novel cholinergic agent with a dual mode of action, which inhibits acetylcholinesterase and allosterically modulates nicotinic acetylcholine receptors (nAChRs), as a result stimulates catecholamine neurotransmission. In the present study, we (...) investigated whether galantamine exerts cognitive improving effects through the allosteric modulation of nAChR in the intracerebroventricular beta amyloid (Abeta)(25-35)-injected animal model of Alzheimer's disease. Galantamine (3 mg/kg p.o.) significantly increased the extracellular dopamine release in the hippocampus of saline- and Abeta(25-35)-injected mice. The effects of nicotine on the extracellular dopamine release were potentiated by galantamine, but antagonized by mecamylamine, a nAChR antagonist

Full Text available with Trip Pro

2007 Neuropsychopharmacology

772. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. (PubMed)

Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Clinical studies suggest that adjunct galantamine may improve negative and cognitive symptoms in schizophrenia. These symptoms may be related to impaired dopaminergic function in the prefrontal cortex. Indeed, galantamine has been shown to increase dopamine release in vitro. Galantamine is an allosteric modulator of nicotinic acetylcholine receptors (nAChRs (...) ) and, at higher doses, an acetylcholine esterase (AChE) inhibitor. We have previously shown that nicotine, through stimulation of nAChRs in the ventral tegmental area (VTA), activates midbrain dopamine neurons and, hence, potentiation of these receptors could be an additional mechanism by which galantamine can activate dopaminergic pathways. Therefore, the effects of galantamine (0.01-1.0 mg/kg s.c.) on dopamine cell firing were tested in anaesthetized rats. Already at a low dose, unlikely to result

Full Text available with Trip Pro

2007 Neuropsychopharmacology

773. Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. (PubMed)

Reversible Pisa syndrome (pleurothotonus) due to the cholinesterase inhibitor galantamine: case report. We report on a case of reversible Pisa syndrome developed after treatment with galantamine in a patient with Alzheimer's disease without previous exposure to neuroleptic or other cholinesterase inhibitors. Complete and persistent resolution of the syndrome was achieved several weeks after botulinum toxin type-A injection.(c) 2004 Movement Disorder Society.

2004 Movement Disorders

774. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. (PubMed)

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Galantamine (Reminyl), a novel agent with a dual mode of action, modulates nicotinic acetylcholine receptors and inhibits acetylcholinesterase. Galantamine has consistently demonstrated a broad range of beneficial effects and has shown sustained benefits in cognitive and functional abilities for at least 12 months in patients with mild-to-moderate Alzheimer's disease (AD (...) ). As pivotal studies demonstrating the efficacy of cholinergic drugs were designed to exclude patients with severer AD, many patients with the advanced stage of this condition are currently not treated due to the lack of demonstrated efficacy in clinical trials. We aimed to investigate whether there was any evidence for the benefits of galantamine in patients with severer disease, by performing a post hoc analysis using data extracted from the population of the two long-term galantamine studies. We

2003 Dementia and Geriatric Cognitive Disorders

775. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. (PubMed)

Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Observations on the neurochemistry of dementia with Lewy bodies (DLB) have suggested that cholinesterase inhibitors (ChEIs) might be beneficial in treating some clinical symptoms of DLB. A 24-week, multicenter open-label study was designed to assess the safety and efficacy of the ChEI galantamine in patients with DLB, and an interim analysis of results was performed at 12 weeks. Efficacy (...) ). Improvements also were found in secondary efficacy variables, including cognitive, functional, activities of daily living, sleep and confusion assessments. Motor scores, as measured by the UPDRS motor subscale, showed mild improvement, which demonstrates that galantamine has no adverse effect on parkinsonian symptoms. Adverse events generally were transient and of mild-to-moderate intensity. Two of the 25 patients discontinued galantamine because of nausea and anorexia. One serious adverse event

2004 Dementia and Geriatric Cognitive Disorders

776. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. (PubMed)

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis. This review was conducted in order to determine the efficacy of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease, and also to determine whether galantamine was a superior pharmacological intervention. Meta-analytic methods were used to analyse the data from eight empirical studies which met the inclusion criteria specified. By finding (...) the mean effect sizes of the treatment on the outcome measures of cognition, it was determined that neither drug was greatly efficacious. However, this result does not necessarily diminish the practical value of the drug. It was also found that galantamine was no better than donepezil at treating cognitive decline in AD.Copyright (c) 2005 John Wiley & Sons, Ltd.

2005 Human psychopharmacology

777. Regulatory authorities review use of galantamine in mild cognitive impairment (PubMed)

Regulatory authorities review use of galantamine in mild cognitive impairment 15695272 2005 02 23 2016 11 24 1756-1833 330 7486 2005 Feb 05 BMJ (Clinical research ed.) BMJ Regulatory authorities review use of galantamine in mild cognitive impairment. 276 Mayor Susan S eng News England BMJ 8900488 0959-8138 0 Cholinesterase Inhibitors 0D3Q044KCA Galantamine AIM IM Cholinesterase Inhibitors therapeutic use Clinical Trials as Topic Cognition Disorders drug therapy Drug Approval Galantamine

Full Text available with Trip Pro

2005 BMJ : British Medical Journal

778. Galantamine Facilitates Acquisition of a Trace-Conditioned Eyeblink Response in Healthy, Young Rabbits (PubMed)

Galantamine Facilitates Acquisition of a Trace-Conditioned Eyeblink Response in Healthy, Young Rabbits Previous work has demonstrated that drugs increasing brain concentrations of acetylcholine can enhance cognition in aging and brain-damaged organisms. The present study assessed whether galantamine (GAL), an allosteric modulator of nicotinic cholinergic receptors and weak acetylcholinesterase inhibitor, could improve acquisition and retention of an eyeblink (EB) classical conditioning task

Full Text available with Trip Pro

2004 Learning & Memory

779. The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. (PubMed)

The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. To examine the effect of galantamine in elderly patients with mild to moderate Alzheimer disease (AD) on reaction time (RT), selective (SA) and alternating attention (AA), errors, and on interindividual and intraindividual variability.Forty-one outpatients with AD were included in an open-label prospective trial and evaluated at baseline and after 8 and 22 weeks (...) attention, but not AA, improved significantly after 22 weeks. A decrease in the number of errors was noted. At several complexity levels, both at 8 and 22 weeks, the interindividual and intraindividual variability decreased. Changes in Mini Mental State Evaluation score were correlated with those in SA.Our study provides arguments that galantamine treatment improves various parameters of the RT, attention, and interindividual and intraindividual variability in elderly AD patients. Because the study

2007 Journal of Clinical Psychopharmacology

780. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. (PubMed)

Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Recent reports suggest that vascular factors play a crucial role in the development and progression of Alzheimer's disease. We aimed to assess vasomotor reactivity in patients with Alzheimer's disease and vascular dementia due to microangiopathy using transcranial Doppler sonography and near-infrared spectroscopy during a CO(2) exposition task.The normalized CO(2 (...) by near-infrared spectroscopy was decreased in patients with vascular dementia, but not in Alzheimer's disease. Galantamine treatment showed a beneficial effect, normalizing these parameters close to age-matched control levels.Our results suggest that Alzheimer's disease is associated with a lack of vasomotor reactivity, which might be associated with disturbed autoregulation indicating a potential risk for a decreased protection of brain tissue against blood pressure changes. Additionally

Full Text available with Trip Pro

2007 Stroke

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>